OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Conditions
- Autosomal Recessive Polycystic Kidney (ARPKD)
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2025-04-15
- Target Recruit Count
- 20
- Registration Number
- NCT04782258
- Locations
- 🇺🇸
Research Site #104, Washington, District of Columbia, United States
🇺🇸Research Site #100, Atlanta, Georgia, United States
🇺🇸Research Site #108, Chicago, Illinois, United States
Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Device: ShamDevice: CT-152 - Digital Therapeutic
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-10-16
- Target Recruit Count
- 386
- Registration Number
- NCT04770285
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Dallas, Texas, United States
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2025-01-20
- Target Recruit Count
- 241
- Registration Number
- NCT04464564
- Locations
- 🇺🇸
Clinical Research Site #840-020, Phoenix, Arizona, United States
🇺🇸Clinical Research Site #840-047, Anaheim, California, United States
🇺🇸Clinical Research Site #840-059, Lafayette, California, United States
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2025-01-20
- Target Recruit Count
- 184
- Registration Number
- NCT04408755
- Locations
- 🇺🇸
Clinical Research Site #840-012, Kissimmee, Florida, United States
🇺🇸Clinical Research Site #840-069, Maitland, Florida, United States
🇺🇸Clinical Research Site #840-083, Maitland, Florida, United States
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2022-06-02
- Target Recruit Count
- 32
- Registration Number
- NCT04398225
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Hollywood, Florida, United States
A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 150
- Registration Number
- NCT04369391
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC, Long Beach, California, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148
- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2024-05-30
- Target Recruit Count
- 95
- Registration Number
- NCT04258839
- Locations
- 🇺🇸
APG Research, Orlando, Florida, United States
🇺🇸Cedar Health Research, Dallas, Texas, United States
🇺🇸Dothan Behavioral Medicine Clinic, Dothan, Alabama, United States
A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2022-08-24
- Target Recruit Count
- 16
- Registration Number
- NCT04241965
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Ormond Beach, Florida, United States
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-10-03
- Target Recruit Count
- 201
- Registration Number
- NCT04186403
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 591
- Registration Number
- NCT04174170
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States